EGRP News Flash - September 16, 2008

NIH Announces Transformative R01 Program

On behalf of the National Institutes of Health (NIH) Roadmap for Biomedical Research, the National Cancer Institute's (NCI) Epidemiology and Genetics Research Program (EGRP) announces the Transformative Research Projects Program (T-R01). This Program is designed to provide a more flexible and engaging avenue for support of investigators testing novel concepts and truly transformative ideas. The primary objective of the T-R01 initiative is to create a program that is specifically designed to support exceptionally innovative, high risk, original and/or unconventional research with the potential to create new or challenge existing scientific paradigms. The T-R01 program is a High Risk/High Reward Demonstration Project supported by the NIH Common Fund, in which novel approaches to peer review and program management will also be piloted.

The NIH Common Fund intends to commit $25 million (total costs) in Fiscal Year 2009 to fund up to 60 applications submitted in response to this FOA. Applicants to this Funding Opportunity Announcement (FOA) must clearly articulate (1) the fundamental issue to be addressed and its overarching importance to the biomedical/behavioral research enterprise, (2) how the studies will either establish new or disrupt existing paradigms, and (3) how the proposed rationale and/or approaches significantly differ from state of the art in the field.

Projects in any area of NIH interest that meet the transformative criteria above are encouraged and will be considered responsive to this FOA. Areas of highlighted need that have been identified through an NIH strategic planning process include functional variation in mitochondria in disease. In addition to their central role in energy metabolism, mitochondria are involved in many key cellular processes such as the formation of reactive oxygen species and apoptosis. Mutations in mitochondrial DNA lead to a diverse collection of diseases that are challenging to diagnose and treat, and where precise mechanisms of disease pathogenesis remain elusive. Mitochondrial dysfunction has also been implicated in aging and in many chronic disease states including cancer. The emphasis should be in the role of mitochondrial mutations in cancer etiology to identify high risk populations.

There is no budget limit per application up to the amount of funding provided for the program as a whole. This FOA uses "Just-in-Time" information concepts (see SF424 (R&R) Application GuideExternal Web Site Policy). It also uses the modular as well as the non-modular budget formats. Specifically, a U.S. organization submitting an application with direct costs in each year of $250,000 or less (excluding consortium Facilities and Administrative [F&A] costs) must use the PHS398 Modular Budget component. U.S. applicants requesting more than $250,000 in annual direct costs and all foreign applicants must complete and submit budget requests using the Research & Related Budget component.

December 29, 2008 is the opening date for this announcement as well as the Letter of Intent Receipt Date. Applications are due by January 29, 2009.

For general questions about cancer epidemiology contact EGRP's Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, and Acting Chief, Host Susceptibility Factors Branch.

  • Access the NIH Guide for Grants and Contracts for details: RFA-RM-08-029External Web Site Policy (R01)

Return to Top